I don't think shareholders should have to vote on
Post# of 30028
Posted On: 09/02/2014 1:19:15 PM
I don't think shareholders should have to vote on adding a billion authorized shares until.....solid LymPro data is presented that assures us we will be successful commercializing LymPro starting December 2014.
I was hoping for a JV Partnership for LymPro before the Sept. 22nd Shareholder meeting. That would have been very reassuring because they wouldn't throw us big up front money like 50 or 100 million dollars unless they knew Lympro would be successful. Without that big JV Partner reassurance, all we as shareholders have is the data that AMBS publishes. I'm not sure the bridge test data is designed by itself to proclaim that reassurance? I think the validation test data to be completed by early December is the data that will be very substantial. It will have over 160 human patients.
Without a LymPro JV Partner how do we fund that validation study? We'll have to pay for that. How do we fund the Eltoprazine clinical trial? How do we pay for all the extra offices we've opened up and the extra people we've hired? These are legitimate questions to be answered before we vote on the billion authorized shares.
Selling shares to LPC at .13 cents to pay for all of this will burn through more shares!
We need strong Lympro data to give us the reassurance we need to move forward without a partner. With strong Lympro data....I might prefer to go it alone. But we need that concrete data for us to make an intelligent vote and for the pps to keep rising sufficiently to up list this year.
I was hoping for a JV Partnership for LymPro before the Sept. 22nd Shareholder meeting. That would have been very reassuring because they wouldn't throw us big up front money like 50 or 100 million dollars unless they knew Lympro would be successful. Without that big JV Partner reassurance, all we as shareholders have is the data that AMBS publishes. I'm not sure the bridge test data is designed by itself to proclaim that reassurance? I think the validation test data to be completed by early December is the data that will be very substantial. It will have over 160 human patients.
Without a LymPro JV Partner how do we fund that validation study? We'll have to pay for that. How do we fund the Eltoprazine clinical trial? How do we pay for all the extra offices we've opened up and the extra people we've hired? These are legitimate questions to be answered before we vote on the billion authorized shares.
Selling shares to LPC at .13 cents to pay for all of this will burn through more shares!
We need strong Lympro data to give us the reassurance we need to move forward without a partner. With strong Lympro data....I might prefer to go it alone. But we need that concrete data for us to make an intelligent vote and for the pps to keep rising sufficiently to up list this year.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼